67. Wasniewska M, Arrigo T, Crisafulli G, et al. Recovery of acanthosis nigricans
under prolonged metformin treatment in an adolescent with normal weight.
In: J Endocrinol Invest. 2009;32:939-940.
68. Tankova T, Koev D, Dakovska L, Kirilov G. Therapeutic approach in insulin
resistance with acanthosis nigricans. Int J Clin Pract. 2002;56(8):578-581.
69. Hermanns-Le T, Hermanns JF, Pierard GE. Juvenile acanthosis nigricans and
insulin resistance. Pediatr Dermatol. 2002;19(1):12-14.
70. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects
of metformin on insulin resistance and hyperandrogenism in polycystic
ovary syndrome. Eur J Endocrinol. 1998;138(3):269-274.
71. Mazza A, Fruci B, Guzzi P, et al. In PCOS patients the addition of low-dose
spironolactone induces a more marked reduction of clinical and biochemical
hyperandrogenism than metformin alone. Nutr Metab Cardiovasc Dis.
2014;24(2):132-139.
72. Kulshreshtha B, Gupta N, Ganie MA, Ammini AC. Effect of metformin
and spironolactone therapy on OGTT in patients with polycystic ovarian
syndrome - a retrospective analysis. Gynecol Endocrinol. 2012;28(10):823-
826.
73. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen
HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus
ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary
syndrome: a randomized study. J Clin Endocrinol Metab. 2000;85(9):3161-
3168.
74. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK. Metformin
therapy improves the menstrual pattern with minimal endocrine and
metabolic effects in women with polycystic ovary syndrome. Fertil Steril.
1998;69(4):691-696.
AUTHOR CORRESPONDENCE
Calvin T. Sung MD, MBA ctsung@hs.uci.edu
